摘要
目的评价英夫利西单抗治疗进展性类风湿关节炎(RA)的疗效和安全性。方法选择80例进展性类风湿关节炎及疾病活动性指数(DAS28)≥3.2患者,随机分两组,对照组40例给予甲氨蝶呤联合来氟米特,治疗组40例给予来氟米特、甲氨蝶呤联合英夫利西单抗治疗。分别在治疗0、6周及22周记录临床、实验室指标数值及关节肿胀及压痛数改善达20%(ACR20)、50%(ACR50)和70%(ACR70)的例数。结果对照组在6周时除关节肿胀数外,其他指标均无显著改善,22周时各项指标均有显著改善。治疗组在6周时各项指标均有改善,22周疗效更为显著具有统计学意义(P<0.05);ACR20在6周、22周ACR50、ACR70疗效均显著好于对照组。两组患者的不良反应发生率低且不严重。结论英夫利西单抗治疗进展性类风湿关节炎具有起效快、疗效显著,安全性较好的特点,值得临床推广与应用。
Objective To evaluate the efficacy and safety of infliximab in the treatment of patients with active rheumatoid arthritis. Methods 80 subjects of active RA were randomly divided into two groups. The control group were received leflunomide and methotrexate, infliximab group（40 cases） were given infliximab combined with same dosal LEF and MTX. The clinical examination, lab parameters, ACR20, ACR50 and ACR70 were recorded at 0, 6 and 22 weeks respectively. Results There were no sinificantly improved in clinical examination and lab parameters in control group except for swollen joint count（SJC） at 6 weeks until at 22 weeks in contrast to infliximab group with all indexs improved at 6 weeks and further better at 22 weeks. Most of improved indexs in infliximab were significantly better than those in the control group at 6 and 22 weeks. The ACR20 at 6 and 22 weeks, ACR50 and ACR70 at 22 weeks have more better efficacy in infilixmab than those in controls. Both in two groups the overall incidence and severity of adverse events were low. Conclusion Infliximab may be a safe, rapid and effective drug for active RA patients.
作者
王春华
WANG Chun-hua(Department of Rheumatology, Heze Municipal Hospital, Heze 274030, Chin)
出处
《中国医药指南》
2017年第19期10-12,共3页
Guide of China Medicine
